Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, 20-Week, Double-Blind and 32-Week Open-Label Study to Evaluate the Efficacy and Safety of X0002 Spray in Relief of the Signs and Symptoms of Subjects With Osteoarthritis of the Lumbar Spine

Trial Profile

A Phase 3, Multicenter, 20-Week, Double-Blind and 32-Week Open-Label Study to Evaluate the Efficacy and Safety of X0002 Spray in Relief of the Signs and Symptoms of Subjects With Osteoarthritis of the Lumbar Spine

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2018

At a glance

  • Drugs Ibuprofen (Primary)
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Techfields Pharma
  • Most Recent Events

    • 10 Sep 2018 Planned initiation date changed from 10 Aug 2018 to 30 Dec 2018.
    • 01 May 2018 Planned End Date changed from 30 Aug 2019 to 30 Mar 2020.
    • 01 May 2018 Planned primary completion date changed from 10 Jan 2019 to 10 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top